Core Viewpoint - Four Seasons Pharmaceutical (00460.HK) announced that its non-wholly owned subsidiary, Xuanzhu Biotechnology Co., Ltd. ("Xuanzhu Bio"), has been included in the Hong Kong Stock Connect and Shenzhen Stock Connect eligible securities list, effective from March 9, 2026. This inclusion is expected to enhance Xuanzhu Bio's shareholder base and improve the liquidity of its shares, benefiting the group's valuation and market performance in the innovative drug sector [1]. Group 1 - Xuanzhu Bio has been added to the eligible securities list for both Hong Kong Stock Connect and Shenzhen Stock Connect [1] - The inclusion is expected to expand Xuanzhu Bio's shareholder base and enhance share trading liquidity [1] - The group anticipates direct benefits from the revaluation of Xuanzhu Bio and its improved market performance [1]

Core Viewpoint - The company, Xuan Zhu Bio-B (02575.HK), has been included in the Hang Seng Composite Index, effective March 9, 2026, reflecting investor recognition of its value and growth potential [1] Group 1: Inclusion in Hang Seng Composite Index - The inclusion in the Hang Seng Composite Index is based on the quarterly review results announced by Hang Seng Indexes Company on February 13, 2026, for the period ending December 31, 2025 [1] - The Hang Seng Composite Index covers the top 95% of listed companies on the Hong Kong Stock Exchange by cumulative market capitalization [1] - Being part of the index is expected to meet the inclusion criteria for the Stock Connect programs, facilitating trading between Hong Kong and mainland Chinese investors [1] Group 2: Implications of Inclusion - The board believes that inclusion in the index will enhance the company's stock liquidity, broaden the investor base, and enrich the shareholder structure [1] - This development is anticipated to further elevate the company's reputation and investment value in the capital market, contributing to its long-term stable growth [1]

Core Viewpoint - The company, 英矽智能 (03696), has been selected by the Hang Seng Index Company to be included in the Hang Seng Composite Index, effective from March 9, 2026. This inclusion is expected to enhance the company's stock liquidity and broaden its investor base through a diversified shareholder structure, reflecting strong recognition of its industry position and business performance in the international capital market [1][4]. Group 1 - The company will be included in the Hang Seng Composite Index starting March 9, 2026 [1][4]. - The inclusion is anticipated to meet the eligibility criteria for trading under the Stock Connect programs (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect) [1][4]. - The board believes this recognition will promote the company's long-term development and enhance stock liquidity [1][4].

Core Viewpoint - Zhongwei Materials (02579) has seen a stock price increase, with a notable rise of over 3% in the morning session, attributed to the announcement of its inclusion in the Stock Connect program starting December 15, 2025 [1] Group 1: Stock Performance - As of the report, Zhongwei Materials' stock price is at 26.92 HKD, with a trading volume of 20.44 million HKD [1] - The stock experienced a rise of 2.36% at the time of reporting [1] Group 2: Business Growth - Changjiang Securities indicates that Zhongwei's business in ternary precursors and cobalt tetroxide is experiencing continuous growth, with an expected growth rate surpassing the industry average [1] - The market share of Zhongwei is on the rise, with expectations for sustained growth in shipments due to the recovery of the ternary precursor market and ongoing growth in cobalt products [1] Group 3: Lithium Resource Development - Zhongwei has established two salt lake lithium mines in Argentina, with an estimated lithium resource exceeding 10 million tons of LCE, which may increase with further exploration [1] - The company plans to confirm the reserves of the lithium mines and will disclose progress in accordance with regulations based on exploration and construction conditions, as well as market demand [1]

Core Viewpoint - The company Zhongwei New Materials (02579) announced that its H-shares will be included in the Stock Connect program starting December 15, 2025, allowing mainland Chinese investors to directly invest in its H-shares listed on the Hong Kong Stock Exchange, which is expected to enhance the investor base and improve trading liquidity of the H-shares [1] Group 1 - The company will have its H-shares included in the Stock Connect program as of December 15, 2025 [1] - This inclusion allows qualified mainland Chinese investors to invest in the company's H-shares through the Shanghai and Shenzhen Stock Exchanges [1] - The move is anticipated to expand the company's investor base and potentially increase the trading liquidity of its H-shares [1]

Core Viewpoint - The company, Silver Noble Pharmaceuticals-B (02591), has announced that its H-shares will be included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025, which is expected to enhance its investor base and trading liquidity [1] Group 1 - The inclusion of H-shares in the Stock Connect programs allows qualified investors from mainland China to directly invest in H-shares through the Shanghai and Shenzhen stock exchanges [1] - The board believes that this inclusion will further expand the company's investor base and increase the trading liquidity of H-shares [1] - The anticipated outcome is an enhancement of the investment value of H-shares and an improvement in the company's reputation in the capital markets [1]

Group 1 - The core viewpoint of the article highlights the significant growth in trading volume and GDR issuance during the "14th Five-Year Plan" period, indicating a robust performance of the Hong Kong-Shanghai Stock Connect program [1] - The cumulative trading volume of the Hong Kong-Shanghai Stock Connect reached 103 trillion yuan, representing a 288% increase compared to the "13th Five-Year Plan" period [1] - A total of 10 new companies completed GDR (Global Depositary Receipt) issuance, raising a total of 3.35 billion USD [1]

Core Viewpoint - Three companies, Zhongxin Co., Ltd. (603091.SH), Hehe Information (688615.SH), and Yinuosi Biotechnology (688710.SH), will begin trading under the "Shanghai-Hong Kong Stock Connect" mechanism starting October 27, 2025, and will be included as eligible securities in the central settlement system [2] Group 1: Company Information - Zhongxin Co., Ltd. (603091) will be traded under the English name "ZHEJIANG ZHON-A" [2] - Hehe Information (688615) will be traded under the English name "INTSIG INFORM-A" [2] - Yinuosi Biotechnology (688710) will be traded under the English name "SHANGHAI INNO-A" [2] Group 2: Trading Mechanism - The trading of these companies will be conducted in Renminbi and will follow the general rules and operational procedures of Hong Kong settlement [2] - The central settlement system will not provide physical stock custody and withdrawal services for these securities [2]

Core Points - Three companies, Zhongxin Co., Ltd. (603091.SH), Hehe Information (688615.SH), and Innos (688710.SH), will start trading under the "Shanghai-Hong Kong Stock Connect" from October 27, 2025 [1] - These companies will be included as eligible securities in the Central Clearing System, with trading conducted in Renminbi [1] - The Hong Kong Clearing will not provide physical stock custody and withdrawal services for these securities [1] Summary by Category Company Information - Zhongxin Co., Ltd. (603091) will be trading under the English name "ZHEJIANG ZHON-A" [2] - Hehe Information (688615) will be trading under the English name "INTSIG INFORM-A" [2] - Innos (688710) will be trading under the English name "SHANGHAI INNO-A" [2] Trading Mechanism - The trading of these companies will follow the general rules and operational procedures of Hong Kong Clearing [1] - The settlement and clearing will be conducted under the continuous net settlement system of the Central Clearing System [1]

Core Viewpoint - The Hong Kong stock brokerage sector has experienced a significant rebound, with the brokerage index rising 150% over the past decade, reaching a historical high, driven by various market factors and policy changes [1][10]. Group 1: Market Performance and Historical Context - The Hong Kong stock market has undergone approximately seven rounds of brokerage rallies from January 2013 to August 2025, showcasing its volatility and recovery capability [1]. - The first major rally from March 2014 to May 2015 saw the Hong Kong Securities Index increase by 162%, while the Hang Seng Index rose by 32% [4]. - Subsequent rallies included a 21% increase in the Hong Kong Securities Index from February to April 2016 and a 20% increase from December 2017 to January 2018 [5][6]. - The most recent rally from September 2024 to now has resulted in a 151% increase in the Hong Kong Securities Index, with a 40% rise in the Hang Seng Index, indicating a significant outperformance of 111% [9]. Group 2: Factors Driving the Market - The initial rally was fueled by expectations surrounding the Shanghai-Hong Kong Stock Connect, increased corporate financing activities, and a loose liquidity environment [1]. - The second rally was supported by rising international oil prices and policy measures such as reserve requirement cuts in mainland China, alongside the anticipation of the Shenzhen-Hong Kong Stock Connect [2]. - Major policy reforms in 2017, particularly new listing rules by the Hong Kong Stock Exchange, attracted substantial southbound capital and provided new growth drivers for the brokerage sector [3]. - The COVID-19 pandemic in 2020 led to a significant increase in global liquidity, accelerating the return of Chinese concept stocks to Hong Kong, which boosted brokerage business growth [7]. - Recent market improvements have been attributed to favorable policies and enhanced market sentiment, particularly benefiting Chinese brokerages in underwriting and placement activities [8]. Group 3: Future Outlook - The current brokerage market is characterized by significant policy support, active international and domestic capital responses, and rapidly expanding trading volumes [10]. - The valuation of the brokerage sector is recovering quickly, although individual stock performance shows notable divergence, with some stocks still at historical lows and possessing recovery potential [10]. - Future performance of the Hong Kong brokerage sector will be influenced by global liquidity, policy directions, and corporate fundamentals, making it a sector to watch for investment opportunities [10].